Cargando…
Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal c...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373844/ https://www.ncbi.nlm.nih.gov/pubmed/32698898 http://dx.doi.org/10.1186/s13287-020-01804-6 |